US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Holdings

3,206.87

-73.1577-2.23%

Number of Gainers:25

Number of Losers:46

Number of Flat:2

PE:- -

High:3,306.66

Open:3,280.06

Low:3,204.33

Close:3,280.46

Loading ...

Airbnb Inc. Chief Accounting Officer David C. Bernstein Reports Disposal of Common Shares

Dyne Therapeutics Secures Breakthrough Therapy Designation from FDA for DYNE-101 in Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Inc - Extends Cash Runway Into Q3 2027

THOMSON REUTERS

Dyne Therapeutics Q2 Operating Expenses USD 115.791 Million

THOMSON REUTERS

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Why Alibaba Was Outpacing the Broader Stock Market Today

DoorDash hires head of Spotify ad business, Axios reports

KE Holdings Inc. Announces Share Repurchases in July 2025

Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says

MT Newswires Live

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live

Apple Faces Margin Pressure Due to Tariffs' Impact, BofA Says

MT Newswires Live

BRIEF-Avidity Biosciences Announces Completion Of Enrollment For HARBOR™, The First Global Phase 3 Trial Of Delpacibart Etedesiran (Del-Desiran) For Treatment Of DM1 And Provides Guidance On Regulatory Submission

Sector Update: Financial Stocks Lean Lower Premarket Monday

MT Newswires Live

Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and Neuromuscular Program Progress

Avidity Biosciences Completes Enrollment for Phase 3 HARBOR™ Trial of Delpacibart Etedesiran; Regulatory Submissions in U.S., EU, and Japan Expected in H2 2026

Avidity Biosciences Announces Completion of Enrollment for Harbor™, the First Global Phase 3 Trial of Delpacibart Etedesiran (Del-Desiran) for Treatment of Dm1 and Provides Guidance on Regulatory Submission

THOMSON REUTERS

Legend Biotech Corporation to Announce Second Quarter 2025 Financial Results

ProQR Announces Upcoming Presentation at RNA Editing Summit

ADVISORY-Alerts wrongly tagged to AMG Holdings withdrawn

Amg: Entered Deal to Acquire a Minority Equity Interest in Montefiore Investment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4505/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4505","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4505\",,,,,undefined,":{"symbol":"BK4505","market":"US","secType":"PLATE","nameCN":"Hillhouse Capital Holdings","latestPrice":3207.3025,"timestamp":1754066524800,"preClose":3280.4602,"halted":0,"volume":263297011,"delay":0,"changeRate":-0.022301,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-73.157715,"latestTime":"08-01 12:42:04 EDT","open":3280.0647,"high":3306.6597,"low":3204.3303,"amount":19349321101.354874,"amplitude":0.031194,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1754078400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.546119,"peRate":27.252735,"turnoverRate":0.00655,"increases":25,"decrements":46,"flats":2,"marketCap":5911163150367,"floatMarketCap":5529469452468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4505\",,,,,undefined,":{"symbol":"BK4505","high":3306.6597,"amplitude":0.031194,"preClose":3280.4602,"low":3204.3303,"pbRate":"8.546119","latestPrice":3206.8699,"volume":263258134,"delay":0,"open":3280.0647,"prevYearClose":3417.1636,"prevWeekClose":3365.1438,"prevMonthClose":3280.4602,"prevQuarterClose":3213.6726,"fiveDayClose":3365.1438,"twentyDayClose":3302.439,"sixtyDayClose":2985.469,"secType":"PLATE","market":"US","turnoverRate":0.006549,"peRate":27.252735,"marketCap":5910122409215,"floatMarketCap":5528442230924,"timestamp":1754066523164,"nameCN":"Hillhouse Capital Holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4505\",,,,undefined,":{"bkCode":"BK4505","up":25,"down":46,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4505\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555370994","title":"Airbnb Inc. Chief Accounting Officer David C. Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2555370994","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555370994?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:10","pubTimestamp":1753733455,"startTime":"0","endTime":"0","summary":"David C. Bernstein, Chief Accounting Officer at Airbnb Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Airbnb Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL6ShlSg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BZ9MQY76.HKD","IE00B19Z9P08.USD","ABNB","BK4535","BK4505","BK4561","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4566","BK4142"],"gpt_icon":0},{"id":"2555091257","title":"Dyne Therapeutics Secures Breakthrough Therapy Designation from FDA for DYNE-101 in Treatment of Myotonic Dystrophy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2555091257","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555091257?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:10","pubTimestamp":1753733421,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics Inc., a clinical-stage company focused on treating genetically driven neuromuscular diseases, announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of Myotonic Dystrophy Type 1 . This designation is expected to expedite the development and review process of DYNE-101, underscoring its potential as a transformative treatment for DM1. The company is advancing its clinical trials with the aim of achieving U.S. Accelerated Approval submissions in 2026 and potential commercial launches in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on Ju","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL4Hf2Yl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DYN","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","IE00BGHQF748.EUR","BK4112","BK4505","NDAQ","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD"],"gpt_icon":0},{"id":"2555709970","title":"Dyne Therapeutics Inc - Extends Cash Runway Into Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555709970?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:10","pubTimestamp":1753733400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nPLX63429A:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","DYN","BK4588","BK4505"],"gpt_icon":0},{"id":"2555709901","title":"Dyne Therapeutics Q2 Operating Expenses USD 115.791 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555709901?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:10","pubTimestamp":1753733400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nPLX63429A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","DYN","BK4585","BK4588"],"gpt_icon":0},{"id":"2555107709","title":"Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2555107709","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555107709?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:10","pubTimestamp":1753733400,"startTime":"0","endTime":"0","summary":"- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122842/0/en/Dyne-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4139","BK4588","BK4505","BK4539","BK4007","DYN","LENZ","BK4585","BK4135"],"gpt_icon":0},{"id":"2555706494","title":"Why Alibaba Was Outpacing the Broader Stock Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2555706494","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555706494?lang=en_us&edition=fundamental","pubTime":"2025-07-29 03:13","pubTimestamp":1753729980,"startTime":"0","endTime":"0","summary":"The company has a clear-eyed strategy for advancing the development of artificial intelligence (AI).","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/28/why-alibaba-was-outpacing-the-broader-stock-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1242518857.USD","LU0072913022.USD","LU0501845795.SGD","BK4220","BK4543","LU1051769294.HKD","BK4558","LU1046422090.SGD","LU0128525689.USD","BK4531","LU0918141705.HKD","LU1242518931.SGD","IE00BFMHRM44.USD","BK4548","IE00B0JY6N72.USD","LU1048588211.SGD","BK4505","LU1282648689.USD","BK4587","LU1152091168.USD","BK4122","ALBmain","BK4588","LU1105468828.SGD","LU0067412154.USD","LU1152091754.HKD","LU0348814723.USD","LU0918141887.USD","LU1769817179.HKD","BABA","LU0251143458.SGD","LU0348816934.USD","LU0880133367.SGD","BK4503","BK4554","BK4527","BK4575","BK4533","LU0072462343.USD","LU1051768304.USD","09988","LU2226246903.HKD","BK4607","LU0979878070.USD","LU1515016050.SGD","BK4535","LU1267930227.SGD","BK4524","LU1235294995.USD","BK4579"],"gpt_icon":1},{"id":"2555536705","title":"DoorDash hires head of Spotify ad business, Axios reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2555536705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555536705?lang=en_us&edition=fundamental","pubTime":"2025-07-29 01:30","pubTimestamp":1753723832,"startTime":"0","endTime":"0","summary":"DoorDash (DASH) has hired the head of Spotify’s (SPOT) advertising business as its Chief Revenue Officer, Sara Fischer of Axios reports. Published ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/doordash-hires-head-of-spotify-ad-business-axios-reports-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/doordash-hires-head-of-spotify-ad-business-axios-reports-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4503","BK4585","LU2065170008.USD","LU1852331112.SGD","BK4588","LU2098885051.SGD","BK4536","LU2360107168.USD","LU1804176565.USD","BK4108","BK4548","LU2250418816.HKD","LU2065171402.SGD","LU2362541513.USD","LU1303367103.USD","LU2087625088.SGD","SPOT","LU2362540622.SGD","LU0353189680.USD","LU1983260115.SGD","LU0786609619.USD","LU1861220033.SGD","BK4535","LU2065171311.SGD","BK4122","LU2362541273.HKD","LU2360106780.USD","DASH","LU2265009873.SGD","LU2290526834.HKD","BK4571","BK4209","LU0056508442.USD","LU2065169927.USD","BK4549","BK4505","LU1861215975.USD","BK4551"],"gpt_icon":0},{"id":"2554708912","title":"KE Holdings Inc. Announces Share Repurchases in July 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2554708912","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554708912?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:33","pubTimestamp":1753716820,"startTime":"0","endTime":"0","summary":"KE Holdings Inc. Sponsored ADR Class A ( ($BEKE) ) just unveiled an update. KE Holdings Inc. has announced multiple repurchases of its shares throu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ke-holdings-inc-announces-share-repurchases-in-july-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ke-holdings-inc-announces-share-repurchases-in-july-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0326950275.SGD","LU0359201612.USD","LU0359202008.SGD","LU0463099449.HKD","LU1051768304.USD","LU0651946864.USD","BK4504","LU0651947912.USD","LU1688375341.USD","LU1831875114.USD","BK4145","LU0173614495.USD","BK4548","BK4509","BK4079","BEKE","BK4588","LU1023057109.AUD","KE","BK4585","LU1515016050.SGD","LU1188198961.HKD","LU0244354667.USD","BK4526","LU0287142896.SGD","LU0359201885.HKD","BK4505","LU1051769294.HKD"],"gpt_icon":0},{"id":"2555703884","title":"Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2555703884","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555703884?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:23","pubTimestamp":1753716202,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN), Grifols (GRFS), and Argenx (ARGX) appear to be the least exposed to tariffs and least affected by the preliminary trade deal reached between the US and the European Union, Barclays ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","BK4139","AZN","ARGX","LU0320765992.SGD","LU2417539215.USD","BK4532","BK4585","BK4007","GRFS","GSK","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","BK4588","LU1829250122.USD","BK4568","LU2456880835.USD","BK4505","GSK.UK","BK4156"],"gpt_icon":0},{"id":"2554770274","title":"European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2554770274","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554770274?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:04","pubTimestamp":1753715058,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.78% to 1,489.58 on the S&P Europe Select ADR Index.From continental Europe, th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4169","BK4201","SQNS","LU1093756325.SGD","LU1093756168.USD","TRVG","BK4107","LU0320765646.SGD","BUD","NCNA","BK4007","IE00BZ1G4Q59.USD","TEF","BK4559","BK7104","BK4141","LU0162691827.USD","BK4139","ADAP","BK4532","LU1829250122.USD","NVO.AU","BUD.AU","AFG","BCYC","AMRN","LU0154236417.USD","BK4115","BK4588","AUTL","IE00BKVL7J92.USD","BK4599","EVAX","DGE.UK","BK4585","MREO","LU0072461881.USD","BK7119","LU1162221912.USD","BK4077","DBVT","CLLS","DEO","BP","BK4505","BK4117","BK4158"],"gpt_icon":1},{"id":"2554177022","title":"Apple Faces Margin Pressure Due to Tariffs' Impact, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2554177022","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554177022?lang=en_us&edition=fundamental","pubTime":"2025-07-28 22:56","pubTimestamp":1753714575,"startTime":"0","endTime":"0","summary":"Apple's  gross margin is facing pressure due to tariffs, with existing guidance of $900 million in tariff-related costs in fiscal Q3 and about $1 billion expected in the September quarter, BofA Securities said in an earnings preview on Monday.\"While tariffs can be a headwind to gross margin again in fiscal Q4, we model that quarter as the trough and subsequent gross margin improvement driven by a better mix of higher average selling price products, including the slim iPhone 'Air,' which we expect Apple to launch this fall,\" BofA said.The slim iPhone, priced $100 above the current Plus model, is expected to drive higher replacement rates while refreshed MacBook Airs and iPad Pros will improve sales, according to the firm.BofA expects Apple to report in-line results for the June quarter and slightly beat the revenue outlook for the September quarter, backed by better iPhone momentum in China and services strength.BofA reiterated its buy rating and a $235 price target.Price: 214.74, Chang","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2381873111.SGD","LU0149725797.USD","LU0661504455.SGD","LU0640476718.USD","LU0072462426.USD","LU1235294995.USD","LU2746668461.USD","LU1244550577.SGD","BK4553","IE00BZ1G4Q59.USD","BK4592","LU0234572021.USD","IE00BJTD4N35.SGD","LU0868494617.USD","LU2237443549.SGD","LU2458330169.SGD","LU0545039389.USD","LU2357305700.SGD","LU0965509101.SGD","LU1003077747.HKD","LU2168564495.EUR","AAPL","IE00BN29S564.USD","LU1718418525.SGD","LU2430703095.HKD","LU0882574139.USD","LU1974910355.USD","LU0964807845.USD","LU0494093205.USD","LU0861579265.USD","LU1366192091.USD","BK4505","LU1291159041.SGD","LU0198837287.USD","SG9999014559.SGD","IE0003U64NQ7.SGD","LU0466842654.USD","LU0683600562.USD","MACW.SI","LU0308772762.SGD","LU0444973449.USD","LU0957808578.USD","LU1582987324.SGD","LU0096362180.USD","LU0820561818.USD","LU2420271590.USD","BK4579","LU1066051498.USD","LU1267930730.SGD","LU2125154778.USD"],"gpt_icon":1},{"id":"2554740307","title":"BRIEF-Avidity Biosciences Announces Completion Of Enrollment For HARBOR™, The First Global Phase 3 Trial Of Delpacibart Etedesiran (Del-Desiran) For Treatment Of DM1 And Provides Guidance On Regulatory Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2554740307","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554740307?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:18","pubTimestamp":1753708723,"startTime":"0","endTime":"0","summary":"BRIEF-Avidity Biosciences Announces Completion Of Enrollment For HARBOR, The First Global Phase 3 Trial Of Delpacibart Etedesiran (Del-Desiran) For Treatment Of DM1 And Provides Guidance On Regulatory","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUA1FVGRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNA","BK4505","BK4585","BK4588"],"gpt_icon":0},{"id":"2554772890","title":"Sector Update: Financial Stocks Lean Lower Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2554772890","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554772890?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:16","pubTimestamp":1753708564,"startTime":"0","endTime":"0","summary":"Financial stocks were leaning lower premarket Monday with the Financial Select Sector SPDR Fund  marginally declining recently.The Direxion Daily Financial Bull 3X Shares  was 0.1% higher and its bearish counterpart Direxion Daily Financial Bear 3X Shares  was down 0.2%.Interactive Brokers  is considering a stablecoin for customers, Reuters reported, citing an interview with founder Thomas Peterffy. Shares of Interactive Brokers Group were up 0.8% pre-bell.Bank of Hawaii  shares were up more than 1% after the company reported higher Q2 earnings and revenue.AMG  stock was 0.7% higher after the company said it has signed a definitive agreement to acquire a minority equity stake in Montefiore Investment, a European middle-market private equity firm.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1815336091.USD","AMG","LU2237957902.USD","BK4135","LU0757428866.USD","LU2237957811.SGD","BK4211","LU1363072403.SGD","LU0963586101.USD","BK4588","BK4505","BK4598","FAZ","BOH","AMG.AU","FAS","XLF","LU0971096721.USD","IBKR","BK4127"],"gpt_icon":0},{"id":"2554777447","title":"Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and Neuromuscular Program Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2554777447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554777447?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:05","pubTimestamp":1753707939,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Inc. has released a corporate presentation detailing its advancements in RNA therapeutics. The company highlights its proprietary Antibody Oligonucleotide Conjugate  platform, emphasizing its ability to target new tissue and cell types beyond the liver and the flexibility to deploy potent oligonucleotides such as siRNAs and PMOs. The presentation also notes the platform's capability to maximize therapeutic durability, enabling infrequent dosing, and its readiness for scaling. Avidity Biosciences outlines its preparations for building a neuromuscular commercial franchise with three registrational trials and plans for three Biologics License Application submissions within a year. The company reports a solid cash position of approximately $1.4 billion as of March 31, 2025, providing funding into mid-2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLfy8xb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","RNA","BK4585","BK4505"],"gpt_icon":0},{"id":"2554774190","title":"Avidity Biosciences Completes Enrollment for Phase 3 HARBOR™ Trial of Delpacibart Etedesiran; Regulatory Submissions in U.S., EU, and Japan Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2554774190","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554774190?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:01","pubTimestamp":1753707665,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Completes Enrollment for Phase 3 HARBOR Trial of Delpacibart Etedesiran; Regulatory Submissions in U.S., EU, and Japan Expected in H2 2026. Avidity Biosciences Inc., a biopharmaceutical company specializing in RNA therapeutics, announced the completion of enrollment for its Phase 3 HARBOR trial of delpacibart etedesiran  for the treatment of myotonic dystrophy type 1 . This marks a significant milestone in potentially bringing the first approved drug for DM1 to market. The company is on track to share topline data from the study in the second quarter of 2026. Avidity plans to submit marketing applications in the U.S., EU, and Japan starting in the latter half of 2026. Del-desiran has been granted Breakthrough Therapy, Orphan Drug, and Fast Track designations by the U.S. FDA, and Orphan designation by the EMA and in Japan. Currently, no drugs are approved for DM1, making this development crucial for patients living with this rare neuromuscular disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL6mrhyk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4585","RNA","BK4139"],"gpt_icon":0},{"id":"2554741237","title":"Avidity Biosciences Announces Completion of Enrollment for Harbor™, the First Global Phase 3 Trial of Delpacibart Etedesiran (Del-Desiran) for Treatment of Dm1 and Provides Guidance on Regulatory Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2554741237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554741237?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:00","pubTimestamp":1753707607,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUA1FVGRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4585","BK4588","RNA"],"gpt_icon":0},{"id":"2554777963","title":"Legend Biotech Corporation to Announce Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2554777963","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554777963?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:00","pubTimestamp":1753704014,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation will host an investor conference call on August 11, 2025, to review their second-quarter 2025 results. Senior leaders will provide an overview of the company's performance during the quarter. The live audio webcast of the call can be accessed via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours after the call concludes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire  on July 28, 2025, and is solely responsible for the information containe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL6hwXPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4588","BK4585","HK0000306701.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4505","IE00BKPKM429.USD","BK1141","HK0000320264.USD","IE00B3QW5Z07.USD","HK0000320223.HKD","BK4139","01548","LU2210150020.SGD","BK4112","LU2095319765.USD","LU2210149790.SGD","BK1576","HK0000306685.HKD","BK1583","LEGN"],"gpt_icon":0},{"id":"2554197779","title":"ProQR Announces Upcoming Presentation at RNA Editing Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2554197779","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554197779?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:00","pubTimestamp":1753704000,"startTime":"0","endTime":"0","summary":"LEIDEN, Netherlands & CAMBRIDGE, Mass., July  28, 2025  (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122441/33039/en/ProQR-Announces-Upcoming-Presentation-at-RNA-Editing-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU1721428933.USD","LU0702159343.USD","LU0702159699.USD","BK4139","LU2413666426.HKD","BK4106","BK4523","BK4505","LU1543694498.USD","LU2413666699.HKD","LU2229751404.USD","BK4588","LU0347712357.USD","IE00BN0W2W23.USD","LU2092937221.SGD","G","BK4226","BK4585","IE00BN0W2T93.GBP","RNA","SMMF","LU1165135440.EUR","LU1166156734.SGD","A","LU2041044095.USD","LU2089279066.USD","BK4211","BK4121","BK4567"],"gpt_icon":0},{"id":"2554776822","title":"ADVISORY-Alerts wrongly tagged to AMG Holdings withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2554776822","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554776822?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:23","pubTimestamp":1753701831,"startTime":"0","endTime":"0","summary":"ADVISORY-Alerts wrongly tagged to AMG Holdings withdrawnAlerts on US-based investment management company AMG AMG.N acquiring a minority equity interest in Montefiore Investment were incorrectly tagged","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUA5KZQSB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4135","AMG"],"gpt_icon":0},{"id":"2554775615","title":"Amg: Entered Deal to Acquire a Minority Equity Interest in Montefiore Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2554775615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554775615?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:13","pubTimestamp":1753701204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP1HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMG","BK4505","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":11,"totalSize":411,"code":"91000000","status":"200"}]}}